We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Flow Cytometry Speeds Cancer Diagnosis

By Biotechdaily staff writers
Posted on 15 Feb 2006
Cancer researchers using flow cytometry have identified breast cancer cells by detecting fluorescent tags labeling a panel of well-documented biomarkers on their surface membranes.

In flow cytometry, a single frequency laser beam is directed onto a hydrodynamically focused stream of liquid. More...
A number of detectors are aimed at the point where the stream passes through the light beam: one in line with the light beam (forward scatter or FSC), several perpendicular to it (side scatter or SSC), and one or more fluorescent detectors. Each suspended particle passing through the beam scatters the light in some way, and fluorescent chemicals in the particle may be excited into emitting light at a lower frequency than the light source. The detectors pick up this combination of scattered and fluorescent light, and by analyzing fluctuations in brightness at each detector (one for each fluorescent emission peak) it is possible to deduce various facts about the physical and chemical structure of each individual particle. FSC correlates with the cell volume, and SSC depends on the inner complexity of the particle.

Investigators at the University of Illinois (Chicago, USA; ) utilized flow cytometry to detect fluorescent-labeled monoclonal antibodies specific for the estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu that are overexpresssed in the membranes of breast cancer cells.

They reported in the February 2006 issue of Experimental and Molecular Pathology that ER, PR, and HER-2/neu marker expressions in five out of five cell lines were consistent with expression patterns established with time-consuming immunohistochemistry techniques.

"If this technique fulfills its promise, one day soon a lab would receive a tumor tissue sample shipped to us in the morning and have the sample analyzed and typed in time to ship back overnight to the physician making the follow-up treatment decisions,” said senior author Dr. Rafael Nunez, assistant professor of medicine at the University of Illinois. "What now takes weeks or months, with results sometimes coming too late to be useful in treatment decisions, could be done in a matter of hours for a fraction of the current cost.”



Related Links:
University of Illinois, Chicago

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.